Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 23, 2007JAIDS Journal of Acquired Immune Deficiency Syndromes

The Tablet Formulation of Lopinavir/Ritonavir Provides Similar Bioavailability to the Soft-Gelatin Capsule Formulation With Less Pharmacokinetic Variability and Diminished Food Effect

View Full Paper
Ask AI
Bookmark
Share

Authors

CKCheri E. KleinLudwig-Maximilians-Universität MünchenYCYi‐Lin ChiuNational Defense UniversityWAWalid M. AwniAbbVie (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Klein et al. (2007) studied this question.

synapsesocial.com/papers/6a193feaf2eb401dc788d367https://doi.org/10.1097/qai.0b013e31803133c5
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched one closely related paper. Consider it for comparative context:

  1. 1ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease1998 · 473 citations